Bedard PL - Search Results

1

Heterogeneity of Circulating Tumor Cell-Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response.

Kanwar N, Balde Z, Nair R, Dawe M, Chen S, Maganti M, Atenafu EG, Manolescu S, Wei C, Mao A, Fu F, Wang D, Cheung A, Yerofeyeva Y, Peters R, Liu K, Desmedt C, Sotiriou C, Szekely B, Kulka J, McKee TD, Hirano N, Bartlett JMS, Yaffe MJ, Bedard PL, McCready D, Done SJ. Kanwar N, et al. Among authors: bedard pl. Cancer Res. 2021 Dec 15;81(24):6196-6206. doi: 10.1158/0008-5472.CAN-21-1079. Epub 2021 Oct 28. Cancer Res. 2021. PMID: 34711609 Free PMC article.

2

Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?

Bedard PL, Freedman OC, Howell A, Clemons M. Bedard PL, et al. Breast Cancer Res Treat. 2008 Apr;108(3):307-17. doi: 10.1007/s10549-007-9606-8. Epub 2007 May 22. Breast Cancer Res Treat. 2008. PMID: 18351454 Review.

3

Aiming at the target: improved adjuvant medical therapy.

Bedard PL, Dinh P, Sotiriou C, Piccart-Gebhart MJ. Bedard PL, et al. Breast. 2009 Oct;18 Suppl 3:S25-30. doi: 10.1016/S0960-9776(09)70268-1. Breast. 2009. PMID: 19914538 Free article.

4

Decoding the evolution of a breast cancer genome.

Bedard PL, Sotiriou C. Bedard PL, et al. EMBO Mol Med. 2010 Jan;2(1):3-5. doi: 10.1002/emmm.200900054. EMBO Mol Med. 2010. PMID: 20043280 Free PMC article.

5

Doubling back on centromere 17 in early breast cancer.

Bedard PL, Desmedt C. Bedard PL, et al. Lancet Oncol. 2010 Mar;11(3):216-7. doi: 10.1016/S1470-2045(10)70020-6. Lancet Oncol. 2010. PMID: 20202603 No abstract available.

6

Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS).

Toussaint J, Durbecq V, Altintas S, Doriath V, Rouas G, Paesmans M, Bedard P, Haibe-Kains B, Tjalma WA, Larsimont D, Piccart M, Sotiriou C. Toussaint J, et al. PLoS One. 2010 Aug 10;5(8):e12100. doi: 10.1371/journal.pone.0012100. PLoS One. 2010. PMID: 20856894 Free PMC article.

7

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.

Loi S, Symmans WF, Bartlett JM, Fumagalli D, Van't Veer L, Forbes JF, Bedard P, Denkert C, Zujewski J, Viale G, Pusztai L, Esserman LJ, Leyland-Jones BR. Loi S, et al. Lancet Oncol. 2011 Nov;12(12):1162-8. doi: 10.1016/S1470-2045(11)70117-6. Lancet Oncol. 2011. PMID: 21684810

8

Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.

Bedard PL, Singhal SK, Ignatiadis M, Bradbury I, Haibe-Kains B, Desmedt C, Loi S, Evans DB, Michiels S, Dixon JM, Miller WR, Piccart MJ, Sotiriou C. Bedard PL, et al. Endocr Relat Cancer. 2011 Nov 14;18(6):721-30. doi: 10.1530/ERC-11-0180. Print 2011 Dec. Endocr Relat Cancer. 2011. PMID: 21984694

9

Luminal-B breast cancer and novel therapeutic targets.

Tran B, Bedard PL. Tran B, et al. Among authors: bedard pl. Breast Cancer Res. 2011;13(6):221. doi: 10.1186/bcr2904. Epub 2011 Nov 30. Breast Cancer Res. 2011. PMID: 22217398 Free PMC article. Review.

10

Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling.

Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S. Azim HA Jr, et al. Among authors: bedard pl. Clin Cancer Res. 2012 Mar 1;18(5):1341-51. doi: 10.1158/1078-0432.CCR-11-2599. Epub 2012 Jan 18. Clin Cancer Res. 2012. PMID: 22261811 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

245 results

Search Page